Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other financing activities (2017 - 2021)

Historic Other financing activities for Aclaris Therapeutics (ACRS) over the last 5 years, with Q2 2021 value amounting to $300000.0.

  • Aclaris Therapeutics' Other financing activities rose 16479.48% to $300000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was -$289000.0, marking a year-over-year increase of 2589.74%. This contributed to the annual value of -$377000.0 for FY2024, which is 461250.0% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Other financing activities of $300000.0 as of Q2 2021, which was up 16479.48% from -$31000.0 recorded in Q4 2020.
  • Over the past 5 years, Aclaris Therapeutics' Other financing activities peaked at $378000.0 during Q1 2018, and registered a low of -$753000.0 during Q4 2017.
  • For the 5-year period, Aclaris Therapeutics' Other financing activities averaged around -$87642.9, with its median value being -$53500.0 (2018).
  • Per our database at Business Quant, Aclaris Therapeutics' Other financing activities surged by 25131.58% in 2019 and then crashed by 247222.22% in 2020.
  • Over the past 5 years, Aclaris Therapeutics' Other financing activities (Quarter) stood at -$753000.0 in 2017, then soared by 89.91% to -$76000.0 in 2018, then surged by 251.32% to $115000.0 in 2019, then crashed by 126.96% to -$31000.0 in 2020, then surged by 1067.74% to $300000.0 in 2021.
  • Its Other financing activities was $300000.0 in Q2 2021, compared to -$31000.0 in Q4 2020 and -$95000.0 in Q3 2020.